Cancer ResearchUCLA Finds Hidden Weakness in Deadly Small Cell Cancers That Could Unlock New Treatments
UCLA researchers have identified a critical vulnerability in some of the deadliest and hardest-to-treat cancers. Small cell neuroendocrine cancers — which develop in the lung, prostate, and ovary — have seen almost no treatment advances for decades. These tumors typically lose a gene called RB, which normally controls cell growth. The new study found that when RB is missing, cancer cells become heavily dependent on a protein called E2F3 to survive. Blocking E2F3 in laboratory models shut down tumor growth entirely. This mechanism, called synthetic lethality, means cancer cells cannot survive losing both RB and E2F3. Crucially, existing FDA-approved drugs may already be capable of targeting E2F3, potentially accelerating the path to clinical use.
